Evidence map›Paper›PMID 41021200›Full record

ArticlePaediatric drugs2025

History and Current Status of Growth Hormone Treatment in Children.

Camila C Luz, Paulo F Collett-Solberg

Abstract readHistorical Article
PubMed Publisher
In one paragraph

Article in Paediatric drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Camila C LuzLaboratório de Pesquisas Clínicas e Experimentais em Biologia Vascular (BioVasc) and Discipline of Endocrinology, Department of Internal Medicine of Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rua São Francisco Xavier, 524, Pav. Haroldo Lisboa da Cunha sala 104, Maracanã, Rio de Janeiro, RJ, 20550-170, Brazil.ORCID http://orcid.org/0009-0008-9398-8172
Paulo F Collett-SolbergLaboratório de Pesquisas Clínicas e Experimentais em Biologia Vascular (BioVasc) and Discipline of Endocrinology, Department of Internal Medicine of Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rua São Francisco Xavier, 524, Pav. Haroldo Lisboa da Cunha sala 104, Maracanã, Rio de Janeiro, RJ, 20550-170, Brazil. paulosolberg@yahoo.com.ORCID http://orcid.org/0000-0002-6831-8520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth hormone (GH) has been used to treat severe GH deficiency for more than 60 years, with other indications dependent upon approval from national medical societies and governmental agencies. Many changes in GH preparations have been made to improve safety, compliance, and efficacy, from the extraction of GH from human pituitary glands to recombinant hormone technology and from the use of vials and syringes to the use of more advanced devices. Adherence to treatment has always been highlighted as a key point in the success of treatment; new depot preparations permitting weekly administration have advantages in this regard. This review summarizes the history of GH use and provides an analysis of the new weekly administration products.

Indexed as

Growth DisordersHuman Growth HormoneChildHistory, 20th CenturyHistory, 21st CenturyHumansRecombinant ProteinsHuman Growth HormoneRecombinant Proteins

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.